Oxygenta Pharmaceutical (524636) 주식 개요옥시젠타 제약은 인도에서 벌크 의약품과 원료의약품을 제조 및 판매하는 회사입니다. 자세히 보기524636 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석마이너스 주주 지분지난 5년간 매년 수익이 43.3% 감소했습니다.cash runway 경력이 1년 미만입니다.의미 있는 시가총액이 없습니다(₹2B)+ 위험 1건 추가모든 위험 점검 보기524636 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW497,995 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG497,995 investors already sharing narrativesYour Fair Value₹Current Price₹47.2460.3% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-176m3b2016201920222025202620282031Revenue ₹2.5bEarnings ₹368.1mAdvancedSet Fair ValueView all narrativesOxygenta Pharmaceutical Limited 경쟁사Syschem (India)Symbol: BSE:531173Market cap: ₹2.0bAccretion PharmaceuticalsSymbol: NSEI:ACCPLMarket cap: ₹1.8bAccretion NutravedaSymbol: BSE:544694Market cap: ₹1.9bTrident LifelineSymbol: BSE:543616Market cap: ₹3.1b가격 이력 및 성과Oxygenta Pharmaceutical 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹47.2452주 최고가₹119.9052주 최저가₹43.00베타0.471개월 변동-5.05%3개월 변동-4.70%1년 변동-59.29%3년 변동1.66%5년 변동n/aIPO 이후 변동2,149.52%최근 뉴스 및 업데이트New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m).Reported Earnings • Feb 05Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025)Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year.Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025)Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.공시 • Aug 29+ 3 more updatesOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025, at 15:00 Indian Standard Time.더 많은 업데이트 보기Recent updatesNew Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m).Reported Earnings • Feb 05Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025)Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year.Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025)Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.공시 • Aug 29+ 3 more updatesOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025, at 15:00 Indian Standard Time.공시 • Aug 26Oxygenta Pharmaceutical Limited Announces Change in Composition of Committees, Effective August 25, 2025Oxygenta Pharmaceutical Limited at its board meeting held on August 25, 2025 approved change in composition of committees of board effective August 25, 2025. Audit Committee,composed of Sidda Reddy Kanuparthi as Chairman, who is an Additional Director (Independent); Sharvari Swapnil Shinde as Member, also an Additional Director (Independent); Veera Reddy Arava as Member, an Additional Director (Independent); and Chandra Mouliswar Reddy as Member, who is an Additional Director (Executive). In the Nomination and Remuneration Committee, the composition includes Veera Reddy Arava as Chairman, an Additional Director (Independent); Sidda Reddy Kanuparthi as Member, an Additional Director (Independent); and Sharvari Swapnil Shinde as Member, who is an Additional Director (Independent).공시 • Aug 19+ 2 more updatesOxygenta Pharmaceutical Limited Announces Resignation of Vankineni Sai Sudhakar as Managing Director, Effective August 18, 2025Oxygenta Pharmaceutical Limited announced resignation of Vankineni Sai Sudhakar as Managing Director, effective August 18, 2025, due to change in ownership and management of the Company.Reported Earnings • Aug 16First quarter 2026 earnings released: ₹1.65 loss per share (vs ₹0.39 loss in 1Q 2025)First quarter 2026 results: ₹1.65 loss per share (further deteriorated from ₹0.39 loss in 1Q 2025). Revenue: ₹151.3m (up 20% from 1Q 2025). Net loss: ₹61.1m (loss widened 348% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.공시 • Aug 12Oxygenta Pharmaceutical Limited to Report Q1, 2026 Results on Aug 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q1, 2026 results on Aug 14, 2025New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹4.14b market cap, or US$48.2m).New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹4.60b market cap, or US$53.7m).Reported Earnings • Jun 02Full year 2025 earnings released: ₹2.86 loss per share (vs ₹1.09 loss in FY 2024)Full year 2025 results: ₹2.86 loss per share (further deteriorated from ₹1.09 loss in FY 2024). Revenue: ₹1.11b (up 179% from FY 2024). Net loss: ₹103.0m (loss widened 196% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.공시 • May 26Oxygenta Pharmaceutical Limited to Report Q4, 2025 Results on May 30, 2025Oxygenta Pharmaceutical Limited announced that they will report Q4, 2025 results on May 30, 2025Reported Earnings • Feb 16Third quarter 2025 earnings released: ₹1.07 loss per share (vs ₹0.99 loss in 3Q 2024)Third quarter 2025 results: ₹1.07 loss per share (further deteriorated from ₹0.99 loss in 3Q 2024). Revenue: ₹336.9m (up 268% from 3Q 2024). Net loss: ₹39.3m (loss widened 17% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 08Oxygenta Pharmaceutical Limited to Report Q3, 2025 Results on Feb 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q3, 2025 results on Feb 14, 2025Reported Earnings • Nov 18Second quarter 2025 earnings released: EPS: ₹0.81 (vs ₹0.87 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.81 (up from ₹0.87 loss in 2Q 2024). Revenue: ₹147.5m (up 13% from 2Q 2024). Net loss: ₹28.5m (loss narrowed 9.7% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.공시 • Nov 09Oxygenta Pharmaceutical Limited to Report Q2, 2025 Results on Nov 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q2, 2025 results on Nov 14, 2024공시 • Sep 12Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Location: survey no. 252/1,aroor village, sadasivapet mandal, sangareddy district, telangana - 502291, sangareddy IndiaReported Earnings • Aug 16First quarter 2025 earnings released: ₹0.39 loss per share (vs ₹1.65 loss in 1Q 2024)First quarter 2025 results: ₹0.39 loss per share (improved from ₹1.65 loss in 1Q 2024). Revenue: ₹126.4m (up 84% from 1Q 2024). Net loss: ₹13.6m (loss narrowed 70% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.공시 • Aug 09Oxygenta Pharmaceutical Limited to Report Q1, 2025 Results on Aug 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q1, 2025 results on Aug 14, 2024공시 • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2024 Results on May 30, 2024Oxygenta Pharmaceutical Limited announced that they will report Q4, 2024 results on May 30, 2024New Risk • May 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹244m). Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹1.30b market cap, or US$15.6m).공시 • May 23Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding from Amigos Molecular Solutions Private LimitedOn May 21, 2024, Oxygenta Pharmaceutical Limited closed the transaction. The company issued 1,700,000 shares to M V S Prasad Reddy, 200,000 shares to Amigos Molecular Solutions Private Limited and 100,000 to Rachamallu Aparna.공시 • Apr 09Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in fundingOxygenta Pharmaceutical Limited announced a private placement to issue 2,000,000 common shares at an issue price of INR 16 per share for the gross proceeds of INR 32,000,000 on April 8, 2024. The transaction will include participation from individual investors M VS Prasad Reddy for 200,000 shares, Rachamallu Aparna for 100,000 shares and Amigos Molecular Solutions Private Limited for 200,000 shares. The transaction has been approved by the shareholders of the company and is subject general shareholders which is to be scheduled on May 09, 2024.Reported Earnings • Nov 18Second quarter 2024 earnings released: ₹0.87 loss per share (vs ₹1.64 loss in 2Q 2023)Second quarter 2024 results: ₹0.87 loss per share. Revenue: ₹130.8m (up 116% from 2Q 2023). Net loss: ₹31.6m (loss widened 35% from 2Q 2023).New Risk • Oct 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹113m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.02b market cap, or US$12.3m).공시 • Oct 12Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance OfficerOxygenta Pharmaceutical Limited at its board meeting held on October 11, 2023, based on the recommendation of Nomination and Remuneration Committee, approved the appointment of Miss. Dolly Mandhan as the Company Secretary of the Company (Membership No. A66040) designated as the Key Managerial Personnel pursuant to the provisions of section 203 of the Companies Act, 2013 and Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from 01st October 2023. Appointment to fill up vacancy due to resignation of Company Secretary. Miss. Dolly Mandhan is an Associate member of the Institute of Company Secretaries of India and a Commerce Graduate from North Maharashtra University. She has over 3 years of experience in dealing in secretarial functions and compliance matters.공시 • Sep 05+ 1 more updateOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023, at 15:00 Indian Standard Time. Location: at the registered office of the Company Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy District, Telangana IndiaNew Risk • Aug 18New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹151m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m).Reported Earnings • Aug 18First quarter 2024 earnings released: ₹1.65 loss per share (vs ₹1.19 loss in 1Q 2023)First quarter 2024 results: ₹1.65 loss per share (further deteriorated from ₹1.19 loss in 1Q 2023). Revenue: ₹68.6m (down 23% from 1Q 2023). Net loss: ₹45.6m (loss widened 169% from 1Q 2023).공시 • Jul 03Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance OfficerOxygenta Pharmaceutical Limited announced that Mr. Veerendra Babu Rangisetti has resigned from the post of company secretary with effect from close of working hours of June 30, 2023. Consequent to his resignation as Company secretary, Mr. Veerendra Babu Rangisetti also ceases to be compliance officer of the Company.Reported Earnings • Jun 04Full year 2023 earnings released: ₹6.36 loss per share (vs ₹0.48 loss in FY 2022)Full year 2023 results: ₹6.36 loss per share (further deteriorated from ₹0.48 loss in FY 2022). Revenue: ₹310.1m (down 49% from FY 2022). Net loss: ₹115.7m (loss widened ₹109.6m from FY 2022).공시 • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2023 Results on May 30, 2023Oxygenta Pharmaceutical Limited announced that they will report Q4, 2023 results on May 30, 2023Reported Earnings • Feb 16Third quarter 2023 earnings released: ₹2.29 loss per share (vs ₹0.15 profit in 3Q 2022)Third quarter 2023 results: ₹2.29 loss per share (down from ₹0.15 profit in 3Q 2022). Revenue: ₹78.7m (down 51% from 3Q 2022). Net loss: ₹32.5m (down ₹34.7m from profit in 3Q 2022).Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹1.64 loss per share (vs ₹0.27 loss in 2Q 2022)Second quarter 2023 results: ₹1.64 loss per share (further deteriorated from ₹0.27 loss in 2Q 2022). Revenue: ₹60.6m (down 61% from 2Q 2022). Net loss: ₹23.4m (loss widened ₹19.5m from 2Q 2022).공시 • Nov 05Oxygenta Pharmaceutical Limited to Report Q2, 2023 Results on Nov 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q2, 2023 results on Nov 12, 2022공시 • Sep 06Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; to appoint a director in place of Sri. Raghavendra Rao Kanuganti, who retires by rotation and being eligible, seeks re-appointment; To consider Re-Appointment of Dr. Sai Sudhakar Vankineni as Managing Director of the Company; and to consider other matters.공시 • Aug 07Oxygenta Pharmaceutical Limited to Report Q1, 2023 Results on Aug 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q1, 2023 results on Aug 12, 2022Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹25.90, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years.Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.15 (down from ₹2.85 in 3Q 2021). Revenue: ₹159.3m (down 45% from 3Q 2021). Net income: ₹2.18m (down 93% from 3Q 2021). Profit margin: 1.4% (down from 10.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.공시 • Feb 09S.S. Organics Limited to Report Q3, 2022 Results on Feb 14, 2022S.S. Organics Limited announced that they will report Q3, 2022 results on Feb 14, 2022Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹30.35, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 237% over the past three years.Reported Earnings • Nov 21Second quarter 2022 earnings released: ₹0.27 loss per share (vs ₹0.67 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₹154.9m (up 85% from 2Q 2021). Net loss: ₹3.88m (loss narrowed 43% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.공시 • Aug 13S.S. Organics Limited announced that it has received INR 40 million in fundingOn August 12, 2021, S.S. Organics Limited closed the transaction. The company issued 4,000,000 shares at issue price of INR 10 per share for gross proceeds of INR 40,000,000. The paid up share capital of the company will be increased to INR 140,213,000 post closing of the transaction.Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹12.19, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years.주주 수익률524636IN PharmaceuticalsIN 시장7D-1.9%3.3%1.0%1Y-59.3%12.6%-1.4%전체 주주 수익률 보기수익률 대 산업: 524636은 지난 1년 동안 12.6%의 수익을 기록한 Indian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 524636은 지난 1년 동안 -1.4%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 524636's price volatile compared to industry and market?524636 volatility524636 Average Weekly Movement8.9%Pharmaceuticals Industry Average Movement6.6%Market Average Movement6.4%10% most volatile stocks in IN Market9.3%10% least volatile stocks in IN Market4.1%안정적인 주가: 524636의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: 524636의 주간 변동성(9%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트1990175n/awww.oxygentapharma.com옥시젠타 제약은 인도에서 벌크 의약품과 활성 의약품 성분을 제조 및 판매하는 회사입니다. 이 회사는 의약품 조제 및 유기 정밀 화학 제품을 제공합니다. 이 회사는 이전에 S.S.더 보기Oxygenta Pharmaceutical Limited 기초 지표 요약Oxygenta Pharmaceutical의 순이익과 매출은 시가총액과 어떻게 비교됩니까?524636 기초 통계시가총액₹1.77b순이익 (TTM)-₹175.72m매출 (TTM)₹1.13b1.5x주가매출비율(P/S)-9.9x주가수익비율(P/E)524636는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표524636 손익계산서 (TTM)매출₹1.13b매출원가₹1.02b총이익₹108.46m기타 비용₹284.18m순이익-₹175.72m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-4.75총이익률9.60%순이익률-15.55%부채/자본 비율-256.7%524636의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 14:25종가2026/07/06 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oxygenta Pharmaceutical Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).
Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m).
Reported Earnings • Feb 05Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025)Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year.
Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025)Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.
공시 • Aug 29+ 3 more updatesOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025, at 15:00 Indian Standard Time.
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).
Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m).
Reported Earnings • Feb 05Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025)Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year.
Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025)Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.
공시 • Aug 29+ 3 more updatesOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025, at 15:00 Indian Standard Time.
공시 • Aug 26Oxygenta Pharmaceutical Limited Announces Change in Composition of Committees, Effective August 25, 2025Oxygenta Pharmaceutical Limited at its board meeting held on August 25, 2025 approved change in composition of committees of board effective August 25, 2025. Audit Committee,composed of Sidda Reddy Kanuparthi as Chairman, who is an Additional Director (Independent); Sharvari Swapnil Shinde as Member, also an Additional Director (Independent); Veera Reddy Arava as Member, an Additional Director (Independent); and Chandra Mouliswar Reddy as Member, who is an Additional Director (Executive). In the Nomination and Remuneration Committee, the composition includes Veera Reddy Arava as Chairman, an Additional Director (Independent); Sidda Reddy Kanuparthi as Member, an Additional Director (Independent); and Sharvari Swapnil Shinde as Member, who is an Additional Director (Independent).
공시 • Aug 19+ 2 more updatesOxygenta Pharmaceutical Limited Announces Resignation of Vankineni Sai Sudhakar as Managing Director, Effective August 18, 2025Oxygenta Pharmaceutical Limited announced resignation of Vankineni Sai Sudhakar as Managing Director, effective August 18, 2025, due to change in ownership and management of the Company.
Reported Earnings • Aug 16First quarter 2026 earnings released: ₹1.65 loss per share (vs ₹0.39 loss in 1Q 2025)First quarter 2026 results: ₹1.65 loss per share (further deteriorated from ₹0.39 loss in 1Q 2025). Revenue: ₹151.3m (up 20% from 1Q 2025). Net loss: ₹61.1m (loss widened 348% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Aug 12Oxygenta Pharmaceutical Limited to Report Q1, 2026 Results on Aug 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q1, 2026 results on Aug 14, 2025
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹4.14b market cap, or US$48.2m).
New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹4.60b market cap, or US$53.7m).
Reported Earnings • Jun 02Full year 2025 earnings released: ₹2.86 loss per share (vs ₹1.09 loss in FY 2024)Full year 2025 results: ₹2.86 loss per share (further deteriorated from ₹1.09 loss in FY 2024). Revenue: ₹1.11b (up 179% from FY 2024). Net loss: ₹103.0m (loss widened 196% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
공시 • May 26Oxygenta Pharmaceutical Limited to Report Q4, 2025 Results on May 30, 2025Oxygenta Pharmaceutical Limited announced that they will report Q4, 2025 results on May 30, 2025
Reported Earnings • Feb 16Third quarter 2025 earnings released: ₹1.07 loss per share (vs ₹0.99 loss in 3Q 2024)Third quarter 2025 results: ₹1.07 loss per share (further deteriorated from ₹0.99 loss in 3Q 2024). Revenue: ₹336.9m (up 268% from 3Q 2024). Net loss: ₹39.3m (loss widened 17% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 08Oxygenta Pharmaceutical Limited to Report Q3, 2025 Results on Feb 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q3, 2025 results on Feb 14, 2025
Reported Earnings • Nov 18Second quarter 2025 earnings released: EPS: ₹0.81 (vs ₹0.87 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.81 (up from ₹0.87 loss in 2Q 2024). Revenue: ₹147.5m (up 13% from 2Q 2024). Net loss: ₹28.5m (loss narrowed 9.7% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
공시 • Nov 09Oxygenta Pharmaceutical Limited to Report Q2, 2025 Results on Nov 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q2, 2025 results on Nov 14, 2024
공시 • Sep 12Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Location: survey no. 252/1,aroor village, sadasivapet mandal, sangareddy district, telangana - 502291, sangareddy India
Reported Earnings • Aug 16First quarter 2025 earnings released: ₹0.39 loss per share (vs ₹1.65 loss in 1Q 2024)First quarter 2025 results: ₹0.39 loss per share (improved from ₹1.65 loss in 1Q 2024). Revenue: ₹126.4m (up 84% from 1Q 2024). Net loss: ₹13.6m (loss narrowed 70% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
공시 • Aug 09Oxygenta Pharmaceutical Limited to Report Q1, 2025 Results on Aug 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q1, 2025 results on Aug 14, 2024
공시 • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2024 Results on May 30, 2024Oxygenta Pharmaceutical Limited announced that they will report Q4, 2024 results on May 30, 2024
New Risk • May 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹244m). Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹1.30b market cap, or US$15.6m).
공시 • May 23Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding from Amigos Molecular Solutions Private LimitedOn May 21, 2024, Oxygenta Pharmaceutical Limited closed the transaction. The company issued 1,700,000 shares to M V S Prasad Reddy, 200,000 shares to Amigos Molecular Solutions Private Limited and 100,000 to Rachamallu Aparna.
공시 • Apr 09Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in fundingOxygenta Pharmaceutical Limited announced a private placement to issue 2,000,000 common shares at an issue price of INR 16 per share for the gross proceeds of INR 32,000,000 on April 8, 2024. The transaction will include participation from individual investors M VS Prasad Reddy for 200,000 shares, Rachamallu Aparna for 100,000 shares and Amigos Molecular Solutions Private Limited for 200,000 shares. The transaction has been approved by the shareholders of the company and is subject general shareholders which is to be scheduled on May 09, 2024.
Reported Earnings • Nov 18Second quarter 2024 earnings released: ₹0.87 loss per share (vs ₹1.64 loss in 2Q 2023)Second quarter 2024 results: ₹0.87 loss per share. Revenue: ₹130.8m (up 116% from 2Q 2023). Net loss: ₹31.6m (loss widened 35% from 2Q 2023).
New Risk • Oct 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹113m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.02b market cap, or US$12.3m).
공시 • Oct 12Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance OfficerOxygenta Pharmaceutical Limited at its board meeting held on October 11, 2023, based on the recommendation of Nomination and Remuneration Committee, approved the appointment of Miss. Dolly Mandhan as the Company Secretary of the Company (Membership No. A66040) designated as the Key Managerial Personnel pursuant to the provisions of section 203 of the Companies Act, 2013 and Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from 01st October 2023. Appointment to fill up vacancy due to resignation of Company Secretary. Miss. Dolly Mandhan is an Associate member of the Institute of Company Secretaries of India and a Commerce Graduate from North Maharashtra University. She has over 3 years of experience in dealing in secretarial functions and compliance matters.
공시 • Sep 05+ 1 more updateOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023, at 15:00 Indian Standard Time. Location: at the registered office of the Company Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy District, Telangana India
New Risk • Aug 18New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹151m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m).
Reported Earnings • Aug 18First quarter 2024 earnings released: ₹1.65 loss per share (vs ₹1.19 loss in 1Q 2023)First quarter 2024 results: ₹1.65 loss per share (further deteriorated from ₹1.19 loss in 1Q 2023). Revenue: ₹68.6m (down 23% from 1Q 2023). Net loss: ₹45.6m (loss widened 169% from 1Q 2023).
공시 • Jul 03Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance OfficerOxygenta Pharmaceutical Limited announced that Mr. Veerendra Babu Rangisetti has resigned from the post of company secretary with effect from close of working hours of June 30, 2023. Consequent to his resignation as Company secretary, Mr. Veerendra Babu Rangisetti also ceases to be compliance officer of the Company.
Reported Earnings • Jun 04Full year 2023 earnings released: ₹6.36 loss per share (vs ₹0.48 loss in FY 2022)Full year 2023 results: ₹6.36 loss per share (further deteriorated from ₹0.48 loss in FY 2022). Revenue: ₹310.1m (down 49% from FY 2022). Net loss: ₹115.7m (loss widened ₹109.6m from FY 2022).
공시 • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2023 Results on May 30, 2023Oxygenta Pharmaceutical Limited announced that they will report Q4, 2023 results on May 30, 2023
Reported Earnings • Feb 16Third quarter 2023 earnings released: ₹2.29 loss per share (vs ₹0.15 profit in 3Q 2022)Third quarter 2023 results: ₹2.29 loss per share (down from ₹0.15 profit in 3Q 2022). Revenue: ₹78.7m (down 51% from 3Q 2022). Net loss: ₹32.5m (down ₹34.7m from profit in 3Q 2022).
Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹1.64 loss per share (vs ₹0.27 loss in 2Q 2022)Second quarter 2023 results: ₹1.64 loss per share (further deteriorated from ₹0.27 loss in 2Q 2022). Revenue: ₹60.6m (down 61% from 2Q 2022). Net loss: ₹23.4m (loss widened ₹19.5m from 2Q 2022).
공시 • Nov 05Oxygenta Pharmaceutical Limited to Report Q2, 2023 Results on Nov 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q2, 2023 results on Nov 12, 2022
공시 • Sep 06Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; to appoint a director in place of Sri. Raghavendra Rao Kanuganti, who retires by rotation and being eligible, seeks re-appointment; To consider Re-Appointment of Dr. Sai Sudhakar Vankineni as Managing Director of the Company; and to consider other matters.
공시 • Aug 07Oxygenta Pharmaceutical Limited to Report Q1, 2023 Results on Aug 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q1, 2023 results on Aug 12, 2022
Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹25.90, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years.
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.15 (down from ₹2.85 in 3Q 2021). Revenue: ₹159.3m (down 45% from 3Q 2021). Net income: ₹2.18m (down 93% from 3Q 2021). Profit margin: 1.4% (down from 10.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
공시 • Feb 09S.S. Organics Limited to Report Q3, 2022 Results on Feb 14, 2022S.S. Organics Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹30.35, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 237% over the past three years.
Reported Earnings • Nov 21Second quarter 2022 earnings released: ₹0.27 loss per share (vs ₹0.67 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₹154.9m (up 85% from 2Q 2021). Net loss: ₹3.88m (loss narrowed 43% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
공시 • Aug 13S.S. Organics Limited announced that it has received INR 40 million in fundingOn August 12, 2021, S.S. Organics Limited closed the transaction. The company issued 4,000,000 shares at issue price of INR 10 per share for gross proceeds of INR 40,000,000. The paid up share capital of the company will be increased to INR 140,213,000 post closing of the transaction.
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹12.19, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years.
